NICE Rejects Bile Duct Cancer Drug
Analysis based on 7 articles · First reported Mar 06, 2026 · Last updated Mar 08, 2026
The initial rejection of zanidatamab by the United Kingdom===National Institute for Health and Care Excellence has created uncertainty for pharmaceutical companies developing new treatments and highlights the challenges of drug approval processes. A potential reversal of this decision could positively impact the market for cancer therapeutics and improve patient outcomes.
The United Kingdom===National Institute for Health and Care Excellence (NICE) initially rejected zanidatamab, a new antibody treatment for cholangiocarcinoma (bile duct cancer), for widespread use within the United Kingdom===National Health Service. This decision has sparked a campaign by patients and their families, including the late Huw Jones and current patient Gareth Honeybone, who have experienced significant benefits from the drug in clinical trials. Allah Made Me Funny, a cholangiocarcinoma charity, has also voiced disappointment. NICE is set to reassess the evidence in March, with advocates hoping for a revised recommendation that would make this life-extending treatment accessible to more patients in the United_Kingdom.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard